Swedish Biotech Startup Epigenica Raises $2.2M to Accelerate Personalized Medicine Through Epigenetic Innovation

The round was led by Voima Ventures, with participation from Navigare Ventures, Leksell Social Ventures, and existing backer Almi Invest. The investment will support the launch of new products, the growth of Epigenica’s data infrastructure, and the expansion of its service offerings.

EpiFinder: A Scalable Platform for Epigenetic Breakthroughs

At the heart of Epigenica’s innovation is its proprietary EpiFinder platform, which allows the simultaneous analysis of multiple epigenetic markers across a large number of samples. This high-resolution, efficient, and cost-effective tool is designed to power drug discovery, development, and multi-omics research.

Unlike traditional genomics, epigenetics focuses on how environmental and lifestyle factors influence gene expression—a growing area of interest in fields like oncology, longevity, and precision medicine.

“Since Epigenica’s founding, we’ve built a diverse product portfolio designed to serve the full range of epigenetics applications,” said Mohamad Takwa, CEO of Epigenica. “This funding will accelerate several major product launches and help us bring our technology to more researchers around the world.”

Backing Science-Driven Innovation

Voima Ventures' Investment Director Stina Wallmark emphasized the potential of epigenetics in transforming healthcare:

“Epigenica enables fast, scalable, and affordable analysis of epigenetic biomarkers, helping researchers fully unlock the potential of multi-omics in the search for new diagnostics and therapies.”

The funding will specifically support the roll-out of new products including EpiFinder Global and EpiFinder cNUC kits, building on the success of EpiFinder Genome, which is already in use.

Toward a New Era in Personalized Medicine

With the rise of multi-omics, researchers now integrate data from genomics, transcriptomics, proteomics, and metabolomics. Epigenica’s work adds a critical layer—epigenetic insight—which can provide a deeper understanding of disease mechanisms and patient-specific treatment responses.

Epigenica’s technology empowers researchers and pharmaceutical companies to better predict treatment outcomes, uncover new therapeutic targets, and personalize medical interventions.

As the company prepares to enter the US market, this funding marks a pivotal step in establishing Epigenica as a global player in next-generation biomedical research.